arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Sionna Therapeutics, Inc.

SION Health Care Biotechnology: Pharmaceutical Preparations
$46.43
▼ -1.9% Today
as of Aug 5, 16:54 ET
Last 30 days +10.17% Jun 29 → Aug 05
$40.98 $43.38 $45.79 $48.20 $50.60 Jun 29 Jul 07 Jul 14 Jul 22 Jul 29 Aug 05
Open
$37.55
High
$37.95
Low
$35.25
Volume
$461,280
Avg Vol
$300,406
Mkt Cap
$2.2B
P/E (TTM)
—
Beta
—
52w High
$48.45
52w Low
$13.51
Div Yield
—
Shares Out
$45M

Recent Press Releases & News last 60 days · 3 items

Jul 9 · 20:54 MT Newswires
Sionna Therapeutics Insider Sold Shares Worth $3,854,281, According to a Recent SEC Filing
Jul 7 · 20:41 MT Newswires
Sionna Therapeutics Insider Sold Shares Worth $446,862, According to a Recent SEC Filing
Jun 11 · 09:12 Simply Wall St.
Assessing Sionna Therapeutics (SION) Valuation After A Mixed Period For Recent Share Price Returns

Overview

52-week range
$14
$48
94% of range
Avg surprise (last 3)
-4.5%
Avg reaction (last 2)
-3.1%
50% positive
Latest IV / EM
376%
EM ±62.7% · $45 · Aug 21

Earnings trends

EPS — actual vs estimate Actual Estimate
$-3840.00$-2880.10$-1920.20$-960.31$-0.41 Actual $-3840.00Actual $-2710.00Actual $-5.67Actual $-0.62Est $-0.45Actual $-0.41Est $-0.68Actual $-0.46Actual $-0.60Est $-0.52 MarJunSepMar/2025Jun/2025SepMar/2026
Revenue vs Net Income Revenue Net income
$-27M$-22M$-18M$-13M$-9M Jun 24Sep 24Mar 25Jun 25Sep 25Mar 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue May 12, 2026Mar/2026 $-0.60 $-0.52 -15.4% +3.2% -10.9% earnings
Tue Sep 30, 2025Sep 2025 $-0.46 — — — — financials
Mon Aug 11, 2025Jun/2025 $-0.41 $-0.68 +39.7% — — earnings
Mon May 12, 2025Mar/2025 $-0.62 $-0.45 -37.8% — +4.7% earnings
Mon Sep 30, 2024Sep 2024 $-5.67 — — — — financials
Sun Jun 30, 2024Jun 2024 $-2710.00 — — — — financials
Sun Mar 31, 2024Mar 2024 $-3840.00 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Mon Aug 10, 2026Jun/2026OTHER -$0.64-$0.41 -56.1%

Financials

Income statement (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-30M—$-24M$-22M$-20M—$-28M$-11M
Net income$-27M—$-20M$-18M$-16M—$-25M$-9M
EPS (diluted)$-0.60—$-0.46$-410.00$-0.62—$-5.67$-2710.00

Balance sheet (quarterly)

MetricMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
Cash & equivalents$63M$58M$51M$41M$83M$38M$36M$44M
Inventory————————
Total current assets$221M$241M$252M$267M$274M$151M——
Total assets$305M$326M$339M$352M$370M$186M——
Long-term debt————————
Total liabilities$17M$19M$18M$16M$18M$19M——
Total equity$288M$307M$322M$336M$352M$-164M$-149M$-134M

Implied volatility — last 90 days

102%171%240%309%378% Jun 08 — IV 129% · EM ±17.0%Jun 09 — IV 129% · EM ±16.2%Jun 10 — IV 136% · EM ±16.0%Jun 11 — IV 131% · EM ±14.4%Jun 12 — IV 147% · EM ±15.0%Jun 15 — IV 207% · EM ±15.0%Jun 19 — IV 103% · EM ±22.7%Jun 22 — IV 114% · EM ±23.8%Jun 23 — IV 110% · EM ±22.6%Jun 24 — IV 115% · EM ±23.0%Jun 25 — IV 124% · EM ±24.2%Jun 26 — IV 107% · EM ±20.4%Jun 29 — IV 119% · EM ±21.1%Jun 30 — IV 115% · EM ±19.8%Jul 01 — IV 116% · EM ±19.3%Jul 02 — IV 116% · EM ±18.7%Jul 03 — IV 120% · EM ±18.7%Jul 06 — IV 134% · EM ±18.6%Jul 07 — IV 139% · EM ±18.4%Jul 08 — IV 129% · EM ±16.2%Jul 09 — IV 139% · EM ±16.5%Jul 10 — IV 139% · EM ±15.3%Jul 13 — IV 176% · EM ±14.7%Jul 14 — IV 243% · EM ±17.6%Jul 15 — IV 198% · EM ±11.7%Jul 16 — IV 270% · EM ±11.3%Jul 20 — IV 238% · EM ±56.2%Jul 21 — IV 272% · EM ±63.2%Jul 22 — IV 291% · EM ±66.6%Jul 23 — IV 305% · EM ±68.7%Jul 24 — IV 299% · EM ±66.1%Jul 27 — IV 320% · EM ±66.8%Jul 28 — IV 332% · EM ±68.0%Jul 29 — IV 349% · EM ±69.8%Jul 30 — IV 343% · EM ±67.1%Jul 31 — IV 312% · EM ±59.7%Aug 03 — IV 349% · EM ±61.8%Aug 04 — IV 378% · EM ±65.2%Aug 05 — IV 376% · EM ±62.7%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,164.75-0.4%
JNJ
Johnson & Johnson
$624.1B $258.23+0.2%
ABBV
AbbVie Inc.
$454.8B $246.35+0.1%
MRK
Merck & Company, Inc.
$321.6B $129.20+0.7%
PM
Philip Morris International Inc
$299.3B $188.93-0.0%
NVS
Novartis AG
$297.9B $154.440.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in